This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, L.-Y. Articles by Plunkett, W. Search for Related Content PubMed PubMed Citation Articles by Yang, L.-Y. Articles by Plunkett, W.

Expression of ERCC1 Antisense RNA Abrogates Gemcitabine-mediated Cytotoxic Synergism with Cisplatin in Human Colon Tumor Cells Defective in Mismatch Repair but Proficient in Nucleotide Excision Repair¹

Division of Pathology and Laboratory Medicine [L-Y. Y., L. L., H. J.], Department of Biostatistics [Y. S.], and Section of Cellular and Molecular Pharmacology, Division of Medicine [W. P.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Gemcitabine, or 2',2'-difluorodeoxycytidine (dFdC) is a new anticancer agent with significant activity against a broad spectrum of tumors either as a single agent or in combination with other active anticancer drugs. Studies in vitro and in vivo have demonstrated that dFdC produces cytotoxic synergism with cisplatin, or cis-diamminedicholoroplatinum(II) (CDDP); however, the mechanism by which the synergism occurs has not been elucidated. We proposed that the nucleotide excision repair (NER) process, which is responsible for the cellular removal of CDDP-DNA adducts, may be a target for the mechanism of the cytotoxic synergism of dFdC and CDDP. Because the mismatch repair (MMR) pathway is involved in mediating CDDP cytotoxicity, making determination of the role of the NER in the cytotoxic synergism more complicated, and because tumors are often defective in MMR, we selected an NER-proficient, MMR-deficient, CP2.0 human colon carcinoma cell line as a model for this study. By an in vitro repair synthesis assay, we found that dFdC triphosphate (dFdCTP), the active metabolite of dFdC, inhibited the incorporation of [-³²P]dATP as well as the incorporation of [-³²P]dCTP, suggesting that the repair inhibition by dFdCTP does not result simply from competition for the incorporation site but rather is also due to prevention of chain elongation during the DNA resynthesis process. To determine whether the repair inhibition contributes to the cytotoxic synergism, we examined the effect of the constitutive expression of ERCC1 antisense RNA on the interaction of dFdC and CDDP. CP2.0 cells were transfected with pERCC1/AS, an ERCC1 antisense expression vector; eight hygromycine-resistant clones expressing various levels of the antisense RNA were selected for quantification of and correlation between the repair activity and cytotoxic synergism. The results show that stable expression of ERCC1 antisense RNA down-regulated the level of mRNA and repair activity; the down-regulation of the repair activity significantly correlated with the reduction of the cytotoxic synergism of the two agents. These data provide direct evidence to support the hypothesis that inhibition of the repair of CDDP-induced DNA lesions plays a critical role in dFdC-mediated cytotoxic synergism with CDDP in MMR-deficient tumor cells.

This article has been cited by other articles:

				V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Schonekas, A. Rost, H. Neuhaus, C. Haag, M. Clemens, B. Heinrich, et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer J. Clin. Oncol., August 20, 2006; 24(24): 3946 - 3952. [Abstract] [Full Text] [PDF]

				L. A. Christensen, R. A. Finch, A. J. Booker, and K. M. Vasquez Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res., April 15, 2006; 66(8): 4089 - 4094. [Abstract] [Full Text] [PDF]

				I.-S. Song, N. Savaraj, Z. H. Siddik, P. Liu, Y. Wei, C. J. Wu, and M. T. Kuo Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells Mol. Cancer Ther., December 1, 2004; 3(12): 1543 - 1549. [Abstract] [Full Text] [PDF]

				S. M. De Lange, C. J. van Groeningen, J. R. Kroep, A. Van Bochove, J. F. Snijders, G. J. Peters, H. M. Pinedo, and G. Giaccone Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer Ann. Onc., March 1, 2004; 15(3): 484 - 488. [Abstract] [Full Text] [PDF]

				R. Rosell, K. D. Danenberg, V. Alberola, G. Bepler, J. J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron, P. Diz, et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients Clin. Cancer Res., February 15, 2004; 10(4): 1318 - 1325. [Abstract] [Full Text] [PDF]

				X. Wu, W. Fan, S. Xu, and Y. Zhou Sensitization to the Cytotoxicity of Cisplatin by Transfection with Nucleotide Excision Repair Gene Xeroderma Pigmentosun Group A Antisense RNA in Human Lung Adenocarcinoma Cells Clin. Cancer Res., December 1, 2003; 9(16): 5874 - 5879. [Abstract] [Full Text] [PDF]

				M. Crul, N. E. Schoemaker, D. Pluim, M. Maliepaard, R. W. M. Underberg, M. Schot, R. W. Sparidans, P. Baas, J. H. Beijnen, N. van Zandwijk, et al. Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3526 - 3533. [Abstract] [Full Text] [PDF]

				M. A. Moufarij, D. R. Phillips, and C. Cullinane Gemcitabine Potentiates Cisplatin Cytotoxicity and Inhibits Repair of Cisplatin-DNA Damage in Ovarian Cancer Cell Lines Mol. Pharmacol., April 1, 2003; 63(4): 862 - 869. [Abstract] [Full Text] [PDF]

				M. Selvakumaran, D. A. Pisarcik, R. Bao, A. T. Yeung, and T. C. Hamilton Enhanced Cisplatin Cytotoxicity by Disturbing the Nucleotide Excision Repair Pathway in Ovarian Cancer Cell Lines Cancer Res., March 15, 2003; 63(6): 1311 - 1316. [Abstract] [Full Text] [PDF]

				C. H. Bosken, Q. Wei, C. I. Amos, and M. R. Spitz An Analysis of DNA Repair as a Determinant of Survival in Patients With Non-Small-Cell Lung Cancer J Natl Cancer Inst, July 17, 2002; 94(14): 1091 - 1099. [Abstract] [Full Text] [PDF]

				R. V. N. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J. M. Sanchez, P. H. Gumerlock, M. Taron, et al. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2002; 8(7): 2286 - 2291. [Abstract] [Full Text] [PDF]

				V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673. [Abstract] [Full Text] [PDF]

				S. R. Patel, V. Gandhi, J. Jenkins, N. Papadopolous, M. A. Burgess, C. Plager, W. Plunkett, and R. S. Benjamin Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation J. Clin. Oncol., August 1, 2001; 19(15): 3483 - 3489. [Abstract] [Full Text] [PDF]

				J. W. G. van Putten, H. J. M. Groen, K. Smid, G. J. Peters, and H. H. Kampinga End-joining Deficiency and Radiosensitization Induced by Gemcitabine Cancer Res., February 1, 2001; 61(4): 1585 - 1591. [Abstract] [Full Text]